In this retrospective cohort of patients with recurrent or metastatic HER2-negative gastric cancer receiving first-line nivolumab plus chemotherapy, we found that PD-L1 expression was associated with different clinical outcomes. The gene discussed is CD274; the disease is gastric cancer.